Structure-Based Virtual Screening for Low Molecular Weight Chemical Starting Points for Dipeptidyl Peptidase IV Inhibitors

2005 ◽  
Vol 48 (22) ◽  
pp. 6991-6996 ◽  
Author(s):  
Richard A. Ward ◽  
Tim D. J. Perkins ◽  
Jackie Stafford
Keyword(s):  
Molecular Weight ◽  
Virtual Screening ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase Iv ◽  
Low Molecular Weight ◽  
Dipeptidyl Peptidase Iv Inhibitors

Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening

2012 ◽  
Vol 18 (9) ◽  
pp. 4033-4042 ◽  
Author(s):  
Cui Li ◽  
Weiqiang Lu ◽  
Chunhua Lu ◽  
Wen Xiao ◽  
Xu Shen ◽  
...  
Keyword(s):  
Virtual Screening ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase Iv ◽  
Dipeptidyl Peptidase Iv Inhibitors

scholarly journals Virtual Screening of Dipeptidyl Peptidase IV Inhibitors from Zinc Database

2012 ◽  
Vol 56 (8) ◽  
pp. 31-34
Author(s):  
Phani KumarYadla ◽  
Allam Appa Rao ◽  
A. Swaroopa Rani ◽  
M. Naresh Babu
Keyword(s):  
Virtual Screening ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase Iv ◽  
Zinc Database ◽  
Dipeptidyl Peptidase Iv Inhibitors

scholarly journals Identification of Novel Human Dipeptidyl Peptidase-IV Inhibitors of Natural Origin (Part I): Virtual Screening and Activity Assays

PLoS ONE ◽  
2012 ◽  
Vol 7 (9) ◽  
pp. e44971 ◽  
Author(s):  
Laura Guasch ◽  
Maria José Ojeda ◽  
Noemí González-Abuín ◽  
Esther Sala ◽  
Adrià Cereto-Massagué ◽  
...  
Keyword(s):  
Virtual Screening ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase Iv ◽  
Natural Origin ◽  
Origin Part ◽  
Dipeptidyl Peptidase Iv Inhibitors

Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease – Systematic Review and Metanalysis

2020 ◽  
Vol 16 ◽  
Author(s):  
Lucas Ribeiro dos Santos ◽  
Marcio Luis Duarte ◽  
Maria Stella Peccin ◽  
Antônio Ricardo de Toledo Gagliardi ◽  
Tamara Melnik
Keyword(s):  
Hepatic Steatosis ◽  
Grey Literature ◽  
Specific Treatment ◽  
Reducing Power ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase Iv ◽  
Cochrane Library ◽  
Vast Number ◽  
Dpp Iv ◽  
Dipeptidyl Peptidase Iv Inhibitors

Introduction:: Hepatic steatosis is a frequent condition, that afflicts, especially, obese and insulin resistant patients; diagnosis is made, usually, through imaging tests. Despite the high prevalence and risk of complications, there is no specific treatment approved, though a vast number of medications have been tested. Objective:: To determine the efficacy of dipeptidyl peptidase IV inhibitors (i DPP-IV) in the treatment of NAFLD. Methods:: We searched the electronic databases of the Cochrane Library, MEDLINE, EMBASE and LILACS, as well as reference lists of the included studies and grey literature; 9 studies were selected for inclusion. Results:: 7 studies were used for metanalysis, for 3 outcomes. i DPP-IV showed an ALT-reducing power of MD -10.83 [95% CI 35.23 to 13.57] at 3 months and MD -9.27 [95% CI 10.92 to -7.62] at 6 months of intervention, as well as reduction of hepatic steatosis via MRI of SMD 0.10 [95% CI 0.31 to 0.50]; the overall incidence of adverse events was very low. The studies were considered of low and very low quality by the GRADE evaluation. Conclusion:: Because of the poor overall quality of the studies and heterogeneity of the population analyzed, i DPP-IV did not show efficacy on inflammatory markers or fibrosis in patients with NAFLD.

Sign in / Sign up

Export Citation Format

Share Document